enbezotinib (TPX-0046)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

Src kinase inhibitor, RET inhibitor

Related drugs:

‹

›

RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2
RET mutation	Non Small Cell Lung Cancer	RET mutation	Non Small Cell Lung Cancer	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2

Associations
(2)